Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on AG-120 PK in Healthy Adults
NCT02831972Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML) and cholangiocarcinoma (CCA), sponsored by Agios Pharmaceuticals. Primary endpoints: AG120 Area Under the Curve at 21 days, AG120 Maximum Plasma Concentration at 21 days and 2 more. Started Jun 2016; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02831972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831972.